Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. aloneMultiple milestones...
-
ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market...
-
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing...
-
ZUG, Sviss, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Taugaverndandi þróunarlyfið Privosegtor hefur fengið stöðu byltingarkennds meðferðarlyfs (e. Breakthrough Therapy Designation) til meðhöndlunar á...
-
ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is...
-
ZUG, Switzerland, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...
-
ZUG, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments ...
-
ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...
-
ZUG, Switzerland, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment ...
-
ZUG, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachment ...